Oncolytics Biotech (ONCY) Return on Sales (2009 - 2025)

Oncolytics Biotech's (ONCY) quarterly Return on Sales came in at 1.46% in Q3 2025, up 498.0% year-on-year from 0.24% in Q3 2024, and up 141.56% on a QoQ basis from 3.52% in Q3 2024.

Oncolytics Biotech (ONCY) Return on Sales (2009 - 2025) Analysis & Trends

Oncolytics Biotech (ONCY) has 10 years of Return on Sales data on file, last reported at 1.46% in Q3 2025.

  • On a quarterly basis, Return on Sales rose 498.0% year-over-year to 1.46% in Q3 2025; TTM through Sep 2025 was 0.0%, a 0.0% change from a year earlier, with the FY2018 full-year figure at 0.01%, changed N/A from the prior year.
  • Return on Sales for Q3 2025 stood at 1.46%, up from 3.52% in the prior quarter.
  • Over the last five years, Return on Sales for ONCY reached as high as 1.46% in Q3 2025 and fell as low as 3.52% in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.00%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 0.00%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.00%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 0.00%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Oncolytics Biotech 372.40 Mn 372.40 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 1.46%
Sep 30, 2024 -3.52%
Sep 30, 2020 0.00%
Jun 30, 2020 0.00%
Mar 31, 2020 0.00%
Sep 30, 2019 0.00%
Jun 30, 2019 0.00%
Mar 31, 2019 0.00%
Dec 31, 2018 0.00%
Sep 30, 2018 2.09%
Jun 30, 2017 0.00%
Jun 30, 2016 0.04%
Jun 30, 2011 0.05%
Sep 30, 2010 0.21%
Jun 30, 2010 -0.06%
Dec 31, 2009 0.00%
Sep 30, 2009 0.00%
Jun 30, 2009 0.00%
Mar 31, 2009 0.00%